A5013039829- Wnt/β-catenin signaling in development and cancer
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Glycogen Storage Diseases and Myoclonus
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Carbohydrate Chemistry and Synthesis
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer-related gene regulation
- Gastrointestinal Tumor Research and Treatment
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Renal cell carcinoma treatment
- Cancer-related Molecular Pathways
Brown University
2016-2025
John Brown University
2004-2025
University Health System
2025
Lifespan
2006-2024
Providence College
2015-2024
Rhode Island Hospital
2015-2024
Warren Alpert Foundation
2022-2023
LifeSpan Medical Institute
2020-2022
Miriam Hospital
2007-2020
Cancer Institute (WIA)
2020
Purpose To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Pharmaceutical Research Development, Beerse, Belgium) to standard gemcitabine therapy improves overall survival in advanced pancreatic cancer. Patients Methods This randomized, double-blind, placebo-controlled study compared + versus placebo patients with adenocarcinoma previously untreated systemic therapy. Tipifarnib was given at 200 mg bid orally continuously; 1,000 mg/m...
Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared fluorouracil.To determine if the addition of adjuvant fluorouracil chemoradiation (chemotherapy plus radiation) improves survival for resected adenocarcinoma.Randomized controlled phase 3 trial complete gross total resection adenocarcinoma and no prior radiation or chemotherapy enrolled between July 1998 2002 follow-up through August 18, 2006, at 164 US Canadian...
Percutaneous Radiofrequency Ablation of Malignancies in the LungDamian E. Dupuy1, Ronald J. Zagoria2, Wallace Akerley1, William W. Mayo-Smith1, Peter V. Kavanagh2 and Howard Safran3Audio Available | Share
Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti–programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods In this phase Ib, multicenter, expansion cohort, carcinoma progressing after platinum-based chemotherapy unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were tolerability. Secondary included confirmed objective response rate...
To retrospectively evaluate long-term survival, local tumor progression, and complication rates for all percutaneous computed tomographic (CT)-guided lung radiofrequency (RF) ablations performed at a tertiary care cancer hospital in patients who refused or were not candidates surgery.This HIPAA-compliant study was approved by the institutional review board; informed consent waived. Between 1998 2005, 153 consecutive (mean age, 68.5 years; range, 17-94 years) with 189 primary metastatic...
Purpose CA 19-9 is an important tumor marker in patients with pancreatic adenocarcinoma. A secondary end point of Radiation Therapy Oncology Group trial 9704 was prospective evaluation the ability postresectional to predict survival. Methods expression analyzed as a dichotomized variable (< 180 v ≥ 180) or (≤ 90 > 90). Cox proportional hazards models were utilized identify impact on overall survival (OS). Actuarial estimates for OS calculated using Kaplan-Meier methods. Results Three...
Abstract BACKGROUND: The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease. METHODS: single‐arm prospective trial included patients with a single painful bone metastasis unremitting score >50 on scale of 0‐100. Percutaneous computed tomography‐guided RFA the temperatures >60°C performed. Endpoints were toxicity and effects before at 2 weeks, 1 month, 3 months after RFA. RESULTS: Fifty‐five completed Grade...
Purpose This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, oxaliplatin followed by capecitabine, radiation therapy in locally advanced pancreatic cancer (LAPC). Patients Methods Treatment-naive eligible patients (n = 69) received intravenous gemcitabine (1,000 mg/m 2 ) (100 every weeks for four doses, (50.4 Gy gross tumor only) with concurrent capecitabine (825 twice daily on treatment days). Cetuximab (500 started day 1 chemotherapy continued...
The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti-programmed death ligand-1 [PD-L1]) after first-line induction chemotherapy GC/GEJC. JAVELIN Gastric 100 was a global, open-label, phase III trial. Eligible patients had untreated, unresectable, human epidermal growth factor receptor 2-negative, locally advanced metastatic GC GEJC. Patients without progressive disease 12 weeks with oxaliplatin plus...
The role of epidermal growth factor receptor (EGFR) inhibition in chemoradiation strategies the nonoperative treatment patients with esophageal cancer remains uncertain. To evaluate benefit cetuximab added to concurrent therapy for undergoing carcinoma. A National Cancer Institute (NCI) sponsored, multicenter, phase 3, randomized clinical trial open biopsy-proven carcinoma esophagus. study accrued 344 from 2008 2013. Patients were weekly cisplatin (50 mg/m2), paclitaxel (25 and daily...
PURPOSE Combined modality therapy for non-small-cell lung cancer (NSCLC) has produced promising results. A multiinstitutional phase II clinical trial was conducted to evaluate the activity and toxicity of paclitaxel, carboplatin, concurrent radiation on patients with locally advanced NSCLC. PATIENTS AND METHODS Forty previously untreated inoperable NSCLC entered onto a study from March 1995 December 1996. On an outpatient basis 7 weeks, received paclitaxel 50 mg/m2 weekly over 1 hour;...
ErbB2 overexpression contributes to the evolution of a substantial group human cancers and signifies poor clinical prognosis. Thus, down-regulation signaling has emerged as new anti-cancer strategy. Ubiquitinylation, mediated by Cbl family ubiquitin ligases, physiological mechanism ErbB receptor down-regulation, this appears contribute induced therapeutic anti-ErbB2 antibodies. Hsp90 inhibitory ansamycin antibiotics such geldanamycin (GA) induce rapid ubiquitinylation ErbB2. However,...
Purpose: To determine the response rate and toxicities of Herceptin gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu. Methods Materials: Patients cancer 2 +/3 + HER-2/neu expression by immunohistochemistry were eligible. received gemcitabine, 1 g/m2/week, 7 8 weeks followed 3 every 4 weeks, Herceptin, mg/kg loading dose, mg/kg/week. Results: Screening logs demonstrated overexpression was 16%. Thirty-four enrolled. Thirty (88%) had cancers (12%)...
Chromosomal translocations in the anaplastic lymphoma kinase (ALK) gene have been identified as oncogenic drivers lung adenocarcinomas and other tumors, recently including rare cases of colorectal carcinoma. We a patient with refractory metastatic carcinoma harboring STRN-ALK fusion who achieved an exceptional clinical benefit to ALK inhibitor ceritinib. Our goal was further define clinicopathologic features ALK-rearranged large cohort. Clinical evaluated by comprehensive genomic profiling...
<h3>Background</h3> We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC/GEJC) previously treated chemotherapy. <h3>Methods</h3> In phase 1b expansion cohort, without disease progression following chemotherapy for GC/GEJC received avelumab 10 mg/kg intravenously every 2 weeks. Endpoints included best overall response,...
4005 Background: If 5FU/Capecitabine sensitized radiotherapy (RT) is beneficial in the adjuvant (adj) management of PA after adj chemotherapy (chemo) controversial. NRG/RTOG 0848 was designed to address this issue. Methods: This a 2 step NCTN randomized (rndmzd) trial. Step 1 rndmzd patients (pts) 5 cycles gemcitabine +/- Erlotinib. pts 6 th cycle same chemo with 50.4 Gy 28 fractions RT (chemo+CRT). eligibility included: R0/R1 resection, M0, ECOG PS 0-1, CA19-9≤180. included > 4 (gem, gem...
Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression HER-2/ neu oncogene patients with adenocarcinoma determine potential role trastuzumab (Herceptin) as a therapeutic agent this disease. Tumor specimens from were analyzed by staining for p185HER2 protein using DAKO immunohistochemical assay. Patients and without immunohistochemistry compared respect clinical pathologic characteristics. HER-2/neu gene amplification was...
To determine the response rate of trastuzumab and irinotecan in HER-2/neu overexpressing advanced colorectal cancer (CRC), frequency expression CRC, evaluate pharmacokinetics a phase II study. Patients were screened for by immunohistochemistry (DAKO HercepTest). Prior chemotherapy was limited to one regimen. Trastuzumab administered weekly (loading dose 4 mg/kg i.v. 2 thereafter). Irinotecan 125 mg/m2, weeks with 2-week rest period. overexpression detected 11 138 (8.0%) tumors (2+ 5 3+ 6...